Pharvaris (PHVS) Operating Income (2020 - 2026)
Pharvaris (PHVS) posted Operating Income of -$51.8 million for Q1 2026, down 100.0% on a QoQ basis from $49106701728.6 billion in Q4 2025, and up 100.0% year-over-year from -$25.9 million in Q1 2025.
Pharvaris (PHVS) Operating Income (2020 - 2026) Analysis & Trends
Pharvaris' Operating Income history runs 7 years deep, the most recent figure standing at -$51.8 million for Q1 2026.
- Quarterly Operating Income rose 100.0% year-over-year to -$51.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4731577626.3 billion (up 110.66% YoY) and the FY2025 annual result came in at -$196.3 million, down 36.96% from the prior year.
- Operating Income was -$51.8 million for Q1 2026 at Pharvaris, down from $49106701728.6 billion in the prior quarter.
- Across five years, Operating Income topped out at $49106701728.6 billion in Q4 2025 and bottomed at -$44375124102.2 billion in Q1 2025.
- A 5-year average of $394294369.4 billion and a median of -$46.7 million in 2024 frame the typical range for Operating Income.
- Peak annual rise in Operating Income reached 34709733639158.36% in 2025, while the deepest fall reached 144276873010187.53% in 2025.
- Pharvaris' Operating Income stood at -$77.2 million in 2022, then plunged by 29308348.24% to -$22621.8 billion in 2023, then soared by 100.0% to -$141.5 million in 2024, then surged by 34709733639158.35% to $49106701728.6 billion in 2025, then slumped by 100.0% to -$51.8 million in 2026.
- Business Quant data shows PHVS's Operating Income at -$51.8 million in Q1 2026, $49106701728.6 billion in Q4 2025, and -$46.37 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Pharvaris | 2.22 Bn | 1.94 Bn | - | -51.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.83 Mn |
| Dec 31, 2025 | 49,106,701,728.61 Bn |
| Sep 30, 2025 | -46.37 |
| Mar 31, 2025 | -44,375,124,102.22 Bn |
| Dec 31, 2024 | -141.48 Mn |
| Sep 30, 2024 | -41.63 Mn |
| Mar 31, 2024 | -30.76 Mn |
| Mar 31, 2023 | -22,621.78 Bn |
| Dec 31, 2022 | -77.19 Mn |
| Sep 30, 2022 | -22,571.90 Bn |
| Jun 30, 2022 | -22.82 Mn |
| Mar 31, 2022 | -21.75 Mn |
| Dec 31, 2021 | -48.80 Mn |
| Sep 30, 2021 | -15.72 Mn |
| Jun 30, 2021 | -15.32 Mn |
| Mar 31, 2021 | -14.29 Mn |
| Dec 31, 2020 | -12.91 Mn |
| Sep 30, 2020 | -7.33 Mn |
| Jun 30, 2020 | -6.31 Mn |
| Mar 31, 2020 | -3.58 Mn |